Investigation and pending actions against for Fosamax-related injuries, including reports of osteonecrosis of the jaw.
Fosamax, marketed by Merck, is indicated for the treatment and prevention of osteoporosis (thinning of the bones) in men and women. Recent studies, however, suggest a link between the use of bisphosphonates, such as Fosamax, and osteonecrosis of the jaw, also known as 'jaw death.''
This condition is associated with the interference of the blood supply to the bone and the consequential damage that occurs. Osteonecrosis of the jaw can be extremely painful and may lead to additional complications, such as infection, breakdown of the jawbone, and ulcerations in the lining of the mouth. It is not known if discontinuing the use of Fosamax can lower the risk of osteonecrosis of the jaw, because the bisphosphonate medications metabolize slowly and remain in the bones for many years.
Do not change medications without first consulting your doctor.
Name (Stock Symbol)
Merck & Co. Inc. (MRK)
Merck & Co. Inc. is a large pharmaceutical company.
The information provided on ClassAdvocate.com is general in nature,
does not apply to any particular factual situation, and is not and
should not be taken as legal or other professional advice. We make no
commitment or warranty that the factual, legal or any other information
on ClassAdvocate.com, or on any linked website, is accurate, complete,
error-free, or current. As such, you should not rely on such information,
and should seek professional advice if and as you determine appropriate.
ClassAdvocate.com is not a lawyer referral service, and no attorney-client
or confidential relationship is or should be formed by use of the site.
The investigations listed on ClassAdvocate.com are attorney advertisements
and do not in any way constitute a referral or endorsement by ClassAdvocate.com
or any approved or authorized lawyer referral service.